Climb Bio, Inc.
Data quality: 83%
CLYM
Nasdaq
Manufacturing
Chemicals
$7.78
▲
$0.68
(9.58%)
Mkt Cap: 530.47 M
Price
$7.78
Mkt Cap
530.47 M
Day Range
$7.09 — $7.89
52-Week Range
$1.09 — $8.04
Volume
365,233
Open $7.09
50D / 200D Avg
$6.26
24.30% above
50D / 200D Avg
$3.27
137.72% above
Quick Summary
Key Takeaways
Negative free cash flow of -54.54 M
Growth
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Quality
Return on Equity
-33.00%
Above sector avg (-53.41%)
ROIC-29.50%
Net MarginN/A
Op. MarginN/A
Safety
Debt / Equity
N/A
Current Ratio18.38
Interest CoverageN/A
Valuation
PE (TTM)
-8.86
Below sector avg (-1.48)
P/B Ratio3.00
EV/EBITDAN/A
Dividend YieldN/A
Price History
Financial Trends
Peer Comparison
vs Manufacturing sector median (1364 peers)
Peer Comparison
vs Manufacturing sector median (1364 peers)| Metric | Stock | Sector Median |
|---|---|---|
| P/E | -8.9 | -1.5 |
| P/B | 3.0 | 1.6 |
| ROE % | -33.0 | -53.4 |
| Net Margin % | — | -41.5 |
| Rev Growth 5Y % | — | 1.8 |
| D/E | — | 0.3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -59.85 M |
| ROE | -33.00% | ROA | -31.95% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -54.54 M |
| ROIC | -29.50% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 18.38 |
| Interest Coverage | N/A | Asset Turnover | N/A |
| Working Capital | 86.02 M | Tangible Book Value | 177.00 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -8.86 | Forward P/E | N/A |
| P/B Ratio | 3.00 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -10.28% | ||
| Market Cap | 530.47 M | Enterprise Value | 504.67 M |
| Per Share | |||
| EPS (Diluted TTM) | -0.88 | Revenue / Share | N/A |
| FCF / Share | -0.80 | OCF / Share | -0.80 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 91.13% |
| SBC-Adj. FCF | -64.48 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -59.85 M | -73.90 M | -35.12 M | -45.24 M | -47.48 M |
| EPS (Diluted) | -0.88 | -1.53 | -1.30 | -1.72 | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -67.88 M | -82.02 M | -40.28 M | -45.14 M | -35.67 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 46.71 M | 14.18 M | 15.41 M | 26.21 M | 22.05 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | 97,000.0 | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Income Tax | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 167.74 M | 217.19 M | 110.47 M | 134.99 M | 173.24 M |
| Total Liabilities | 7.27 M | 5.31 M | 2.87 M | 6.28 M | 6.04 M |
| Shareholders' Equity | 160.48 M | 211.88 M | 107.60 M | 128.72 M | 167.20 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 35.69 M | 87.23 M | 93.11 M | 43.59 M | 46.92 M |
| Current Assets | 105.85 M | 154.87 M | 110.26 M | 134.39 M | 148.25 M |
| Current Liabilities | 6.98 M | 4.93 M | 2.83 M | 6.10 M | 6.03 M |
{"event":"ticker_viewed","properties":{"ticker":"CLYM","listing_kind":"stock","pathname":"/stocks/clym","exchange":"Nasdaq","country":"US"}}